Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 160

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 160
---
 trade secrets and intellectual property by maintaining physical security of its premises and physical and electronic security of its information technology systems. Agreements or security measures may be breached, and NLS may not have adequate remedies for any breach. In addition, its trade secrets and intellectual property may otherwise become known or be independently discovered by competitors. NLS cannot provide any assurances that its trade secrets and other confidential proprietary information will not be disclosed in violation of its confidentiality agreements or that competitors will not otherwise gain access to its trade secrets or independently develop substantially equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of its trade secrets and intellectual property could impair its competitive position and may have a material adverse effect on its business. Additionally, if the steps taken to maintain its trade secrets and intellectual property are deemed inadequate, NLS may have insufficient recourse against third parties for misappropriating any trade secret. Third parties may initiate legal proceedings alleging that NLS is infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business. NLS’s commercial success depends upon its ability to develop, manufacture, market and sell its product candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the pharmaceutical industry. While no such litigation has been brought against it and NLS has not been held by any court to have infringed a third party’s intellectual property rights, NLS cannot guarantee that its product candidates or use of its product candidates do not infringe third -partypatents. It is also possible that NLS has failed to identify relevant third -partypatents or applications. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing, which is referred to as the priority date. Therefore, patent applications covering its product candidates could have been filed by others without its knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover its product candidates. 48 NLS may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to its product candidates, including inter parties review, interference, or derivation proceedings before the U.S. PTO and similar bodies in other countries. Third parties may assert infringement claims against it based on existing intellectual property